ascopubs.org

Global clinical experience with adjuvant oxaliplatin/5-fluorouracil (5-FU)-based chemotherapy for colon cancer: Outcomes of the ACCElox registry.

Analysis of totally implantable venous access port systems (TIVAPS) related adverse events (AEs) in metastatic colorectal cancer (mCRC) patients treated with and without bevacizumab.
MedPage Today

Study Backs Skipping 5-FU Bolus in Chemo Regimens for Gastrointestinal Cancers

Omitting bolus 5-fluorouracil (5-FU) from combination chemotherapy for gastrointestinal (GI) cancers did not adversely affect survival and was associated with less toxicity, a review of a large ...
Cure Today

Breaking Down the FDA Labeling Update of Xeloda and 5-FU in Cancer Care

The FDA highlights increased toxicity risks in patients with DPD deficiency when using Xeloda and 5-FU, urging genetic testing before treatment. DPD deficiency leads to severe side effects from ...
ascopubs.org

Oxaliplatin in combination with 5-fluorouracil (FU) in a 48-hour continuous infusion (CI) as first-line chemotherapy for elderly patients (pts) with metastatic colorectal ...

Capecitabine (CAP) versus 5-fluorouracil (FU) in combination with oxaliplatin (OX) as 1st-line chemotherapy (CT) for advanced colorectal cancer (ACRC): Meta-analysis of randomized clinical trials (RCT ...
GEN

Old Chemo Drug Is New Again Because It Can Attack Different Cancers Differently

Since the 1950s a chemotherapy drug known as 5-fluorouracil (5-FU) has been used to treat many types of cancer, including blood cancers and cancers of the digestive tract. Doctors have long believed ...